Issue 4, 2020

The chemical biology of IL-12 production via the non-canonical NFkB pathway

Abstract

Interleukin-12 (IL-12) has emerged as an attractive cytokine for cancer therapy because it has direct anti-cancer effects and additionally plays a critical role in enhancing checkpoint inhibitors. Given these multiple modes of actions, identifying means to pharmacologically induce IL-12 production in the tumor microenvironment has become important. In this review, we highlight therapeutics that promote IL-12 induction in tumor-associated myeloid cells through the non-canonical NFkB pathway. We discuss existing clinical trials and briefly examine the additional pathway targets that warrant further exploration for drug discovery.

Graphical abstract: The chemical biology of IL-12 production via the non-canonical NFkB pathway

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Review Article
Submitted
26 feb 2020
Accepted
13 jul 2020
First published
22 jul 2020
This article is Open Access
Creative Commons BY license

RSC Chem. Biol., 2020,1, 166-176

The chemical biology of IL-12 production via the non-canonical NFkB pathway

P. D. Koch, M. J. Pittet and R. Weissleder, RSC Chem. Biol., 2020, 1, 166 DOI: 10.1039/D0CB00022A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements